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Cancera b s t r a c t
Tumor initiation and progression are the outcomes of a stepwise accumulation of genetic
alterations. Among these, gene ampliﬁcation and aberrant expression of oncogenic proteins, as well
as deletion or inactivation of tumor suppressor genes, represent hallmark steps. Mounting evidence
collected over the last few years has identiﬁed different populations of non-coding RNAs as major
players in tumor suppression in almost all cancer types. Elucidating the diverse molecular
mechanisms underlying the roles of non-coding RNAs in tumor progression might provide
illuminating insights, potentially able to assist improved diagnosis, better staging and effective
treatments of human cancers. Here we focus on several groups of tumor suppressor microRNAs,
whose downregulation exerts a profound oncologic impact and might be harnessed for the beneﬁt
of cancer patients.
 2014 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
In most epithelial tissues, cancer develops through separate and
interrelated steps of clonal expansion, genetic diversiﬁcation, and
clonal selection. During cancer development, cancer cells acquire
diverse biological capabilities that are conferred by numerous
genetic and epigenetic modiﬁcations [1]. In recent years, different
high-throughput platforms have been used for the genomic,
transcriptomic, proteomic, and epigenetic analyses to search for
new biomarkers involved in cancer and to bring new insights into
the several aspects of cancer pathophysiology [1]. In addition to
the classical transcriptional cell regulators involved in cancer
development, a class of non-coding RNAs, termed microRNAs
(miRNAs) has emerged as critical regulators of gene expression act-
ing predominantly at the post-transcriptional level. MiRNAs were
ﬁrst identiﬁed through their ability to regulate developmental
processes, such as developmental timing and cell fate transitions
[2]. Subsequently, miRNAs have been studied in relation to cancer
development. A large number of miRNAs that map to speciﬁc
regions of the human genome have been shown to be frequentlydeleted or ampliﬁed in cancer [3]. Several lines of evidence indicate
that miRNAs might be differentially expressed in cancer cells, in
which they form unique expression patterns or signatures [4].
Sevignani and colleagues reported a signiﬁcant association be-
tween the chromosomal location of miRNAs and those of mouse
susceptibility loci that inﬂuence the development of solid tumors
[5]. Dysregulation of miRNAs in cancer can occur through both epi-
genetic changes, including aberrant DNA methylation and histone
modiﬁcation [6], and genetic alterations. These two biological
mechanisms can affect the production of the primary RNAs, their
processing to the mature miRNA forms, and/or interactions with
mRNA targets [7].
More recent studies indicate that mutations affecting proteins
involved in the processing and maturation of miRNA, such as TAR-
BP2, DICER1 and XPO5, can also lead to overall reductions in miR-
NA expression [8–10]. Consistent with these observations, miRNAs
are thought to act mainly as tumor suppressor genes, and their
deregulation is currently recognized as a common feature of
human cancers. Later on, additional data indicated that the expres-
sion of miRNAs is mainly downregulated in tumor tissues, as
compared to corresponding healthy tissues, which supported the
role of miRNAs as primarily tumor suppressors [4,8,9,11,12]. In
the same vein, there is evidence that an extensive downregulation
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ing cascades downstream to speciﬁc growth factor receptors impli-
cated in a number of human cancers, including breast cancer [13].
For example, EGF signaling rapidly and simultaneously induces an
extensive downregulation of multiple miRNAs, reﬂecting coordi-
nated regulation at the level of miRNA synthesis, processing or
degradation [13].
Along with the dominance of tumor suppressor microRNAs,
several well-characterized oncogenic miRNAs have been reported
in tumors. An interplay between RNA-binding proteins and onco-
genic miRNAs, which drive expression of proto-oncogenes or main-
tenance of stem cell phenotypes, contributes to human cancer [14].
One example relates to oncogenic receptors for growth factors,
such as the EGF-receptor (EGFR/ErbB) family of receptor tyrosine
kinases, the expression of which is regulated by several miRNAs
[15]. In the same vein, signaling pathways are ideal candidates
for miRNA-mediated regulation, owing to the sharp dose-sensitive
nature of their effects. For instance, EGFR activation induces miR-7
expression through a RAS-MYC pathway. In support of this, MYC
binds to and activates the miR-7 promoter and ectopic miR-7 pro-
motes cell growth and tumor formation in lung cancer cells [16].
Thus, in addition to the EGFR/ErbB family, oncogenic miRNAs
(onco-miRs) affect the responsiveness of cells to signaling mole-
cules, such as transforming growth factor-beta, WNT and Notch
[17]. miRNAs control not only cellular proliferation and pro-
grammed cell death, but also dissemination of tumor cells and col-
onization of distant organs (metastasis). Indeed, some miRNAs are
associated with the invasive and metastatic phenotype of breast
and other cancer cell lines or metastatic tumor tissues [18,19].
MiRNAs are also deregulated upon exposure to both metabolic
cancer risk factors and exposures to carcinogenic substances
[20,21]. Thus, miRNAsmay represent at the same time both predic-
tors and players of cancer development. A number of life-style
factors (e.g., diet rich in fats and reﬁned carbohydrates) and path-
ological conditions (e.g., obesity), often related to inﬂammation
and cancer, result in deregulation of speciﬁc miRNAs [22–25]. In
addition, there is evidence of an altered expression of miRNAs in
relation to the exposure to well-known carcinogenic substances
such as asbestos, formaldehyde and cigarette smoke in lung and
hepatic tissue [26,27]. In regard to this evidence, one study exam-
ined the expression of 484 miRNAs in the lungs of rats exposed to
environmental cigarette smoke for 4 weeks. It was found that 126
miRNAs were down-regulated at least 2-fold and 24 miRNAs were
downregulated more than 3-fold [28].
In this review, we highlight the contribution of miRNA modula-
tion, in particular prevalent downregulation of speciﬁc miRNAs, to
cancer development. Due to space consideration, this review
concentrates on a selected group of tumor suppressor microRNAs.
Table 1 lists some additional molecules within this category, which
we do not discuss in the main text. They include miR-34, a p53 tar-
get gene [29,30], miR-31, an inhibitor of metastasis [31], as well as
miR-205 [32], miR-375 [33], miR-203 [34–36], as well as miR-15a
[37–39]. Because many downregulated miRNAs function as tumor
suppressors, better understanding of the biological mechanisms
underlying their modulation will likely enable new strategies for
prevention, early detection and therapy of cancer.
1.1. MiR-10b3p: the early arm of the miR-10b locus
The so-called miRNA-10b locus is located on chromosome 2,
within the cluster of the HOXD genes, in an intergenic region
between HOXD4 and HOXD8 [40]. Processing by Drosha and Dicer
transforms the RNA product of the miRNA-10b locus into a 22-
nucleotide RNA duplex that contains two distinct 50 phosphory-
lated strands with 30 overhangs (Fig. 1). The functional strand of
the duplex, referred to as the guide strand, is miR-10b5p whilethe other, passenger strand generates miR-10b3p. MiR-10b5p
was originally identiﬁed as a molecules down-regulated in primary
breast tumors, compared to normal breast tissues [41]. Similarly,
downregulation of miR-10b5p by promoter hyper-methylation
has been reported in gastric tumors [42]. The Weinberg’s group la-
ter reported that miR-10b5p acts as a metastasis-supporting miR-
NA, due to its ability to favor migration and invasion of breast
cancer cells [43,44]. In line with this, miR-10b5p targets the
HOXD10 gene, a repressor of several modulators of cell migration
[44]. The expression of miR-10b5p is tightly controlled by the
transcription factor Twist, a well-established regulator of epithe-
lial-to-mesenchymal transition (EMT). Increased expression of
miR-10b5p was detected in the vasculature of breast IDC (invasive
ductal carcinoma) grade III tumors, compared to lower expression
in DCIS (ductal carcinoma in situ) [45]. The pleiotropic activity of
miR-10b5p could also rely on its ability to target the expression
of diverse tumor suppressors, including TP53, HODX10, PAX6,
NOTCH1 and FOXO3 (see Table 2) [46].
Biagioni et al. originally reported that the expression of miR-
10b3p was down-regulated in breast tumors, relative to matched
peri-tumoral tissues [12]. This downregulation occurred, at least
in part, through the methylation of CpG islands located within
the regulatory regions of the miR-10b locus [12]. Ectopic expres-
sion of miR-10b3p inhibited proliferation of breast cancer cell lines
and reduced the size of xenografted breast tumors. Three pivotal
proteins involved in the control of cell proliferation, namely
BUB1, PLK1, and CCNA2, were shown to serve as targets of miR-
10b3p. Accordingly, intratumoral injection of a mimic of miR-
10b3p reduced the expression of BUB1, PLK1 and CCNA2 proteins
[12]. The prognostic role of miR-10b3p and of its target was eval-
uated in the MEATBRIC dataset. This analysis included 1286 breast
cancers from 5 different subtypes: HER2+ (127 patients), basal-like
(209 patients), luminal A (479 patients), luminal B (312 patients),
and normal-like (151 patients), for which both mRNA and miRNA
data were available [12]. mRNAs and miRNAs were measured for
each tumoral and normal samples of the METABRIC dataset. Kap-
lan-Meyer analysis revealed a signiﬁcant association between
low expression levels of miR-10b3p and poor disease-speciﬁc sur-
vival [12]. This association was not evidenced for the augmented
expression of miR-10b5p. The combined application of the COSMIC
algorithm [47] and miRanda predictions uncovered 15 target
mRNAs of miR-10b3p [12]. Among those targets three, BUB1,
PLK1 and CCNA2 were conﬁrmed, and additional cell cycle related
targets were also identiﬁed. Increased expression of BUB1, PLK1
and CCNA2 was associated with poor survival (Table 2) [12] .
These ﬁndings have several implications to the roles played by
miR-10b in breast tumorigenesis. Presumably, the expression of
miR-10b3p is altered in the early stages of mammary cell transfor-
mation. This could lead to aberrant cell proliferation, mediated by
increased expression of the cell cycle related targets of miR-10b3p.
In line with early alterations, downregulation of miR-10b3p
expression appears to occur independently from the subtype of
breast cancer, suggesting that it might represent an event preced-
ing speciﬁcation of breast cancer subtypes. Interestingly, the
regulation of the expression of the two strands derived from the
miR-10b locus is controlled by the combination of epigenetic and
transcriptional events. While downregulation of miR10b-3p occurs
through methylation of CpG islands, the transcription factor TWIST
up-regulates the expression of miR-10b5p [44]. This might under-
lie mechanistically the dual and opposite roles of the miR-10b
locus: Early in breast tumorigenesis miR-10b3p downregulation
leads to aberrant cell proliferation, while TWIST-mediated tran-
scriptional induction of miR-10b5p contributes, as a late step, to
shape a metastatic phenotype.
Unlike downregulation of miR-10b3p, which occurs
independently from the breast cancer subtype, up-regulation of
Table 1
Major tumor suppressor microRNAs that are not discussed in the main text of this review.
microRNA Target Function References
miR-34 CDK4
cylinE2
c-Met
CDK6
Notch
HMGA2
BCL-2
SIRT1
AXL
Induces cell cycle arrest and apoptosis
A p53 target gene
Epigenetically silences in some tumors
[29,30]
miR-205 E2F1
LAMC1
Induces senescence and reduces cell proliferation
Directly transactivated by wild type p53
[32]
miR-375 PDK1
14-3-3f
AEG-1
IGF1-receptor
Suppresses cell growth through the AKT pathway
Epigenetically silenced by DNA methylation
[33]
miR-31 Integrin alpha5
RhoA
MMP16
Radixin
WAVE3
Inhibits motility and invasiveness
Induces anoikis
[135]
miR-203 Caveolin 1
LASP1
Reduction of proliferation and inhibition of migration [34–36]
miR-15a Cyclin D1
WNT3A
Crypto
BCL2
Inhibition of ovarian, breast and lung cell proliferation and invasion
Induces apoptosis
[37–39]
Fig. 1. Biogenesis and targets of miRNAs encoded by the miR-10b locus. RNA polymerase II transcribes miRNA genes, generating long primary transcripts (pri miRNAs).
Drosha-mediated cleavage of pri-miRNAs leads to the formation of a hairpin molecule, the pre-miRNA, that is exported to the cytoplasm by the exportin-5/RAN-GTP complex.
In the cytoplasm, the pre-miRNA is cleaved by Dicer, to produce a 22-nt RNA duplex. In the case of the mir-10b locus, these comprise two distinct 50 phosphorylated strands
with 30 overhangs, miR-10b-5p and miR-10b-3p. The functional strand of the duplex is incorporated into a multi-protein complex, the RNA-induced silencing complex (RISC),
which regulates protein expression. In particular, in breast cancer functional miR-10b-3p targets BUB1, PLK1 and CCNA2 mRNAs, inducing a decrease in protein expression
and a consequent inhibition of cancer cell proliferation.
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Table 2
miR-10b locus target genes.
Tissue Target Function References
miR-10b-5p
Glioma TP53
FOXO3
CYLD
PAX6
PTCH1
HOXD10
NOTCH1
Proliferation EMT invasion
angiogenesis
[46]
Breast
cancer
HOXD10 Cell migration and invasion [44]
miR-10b-3p
Breast
cancer
BUB1
PLK1
CCNA2
Inhibition of cancer cell
proliferation
[12]
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breast tumors. Thus, waves of miR-10b3p and 5p targets might
tune the pro-proliferative and pro-metastatic activities of the
aberrantly activated miR-10b locus. Intriguingly, miR-10b3p (pre-
viously named miR-10b⁄) could represent a prototype of miRNAs
derived from passenger strands, which target speciﬁc mRNAs and
exert biological activities as efﬁciently as those originated from
guide strands. While the role of miR-10b5p is relatively well doc-
umented in different human cancers, that of miR-10b3p is poorly
investigated. This also indicates that the miR-10b locus, via down-
regulation of the 3p strand or up-regulation of 5p plays a pivotal
role in breast cancer establishment or dissemination. Once, the
molecular events responsible for aberrant activation of the miR-
10b locus in tumors will be fully understood, they might hold
promise for novel therapeutic strategies. This might turn true also
for passenger derived tumor suppressor miRNAs.
1.2. Let-7c acts as a tumor suppressor miRNA
The let-7 family is one of the most ancient and conserved
groups of miRNAs, showing high conservation across species from
Caenorhabditis elegans to mammals [48]. In humans, the let-7 fam-
ily is comprised of ten members (let-7a, let-7b, let-7c, let-7d, let-
7e, let-7f, let-7g, let-7i, miR-98 and miR202), which differ in their
nucleotide sequences. Some of the isoforms appear in multiple
copies in the genome, hence a number is added as a sufﬁx to their
name (e.g., let-7a-1, let-7a-2 and let-7a-3) (reviewed in [49]).
Interestingly, many of the let-7 miRNAs are located in fragile sites
and speciﬁc genomic regions that relate to cancer [50]. Thus, for
example, in the human genome, the cluster let-7a-1/let-7f-1/let-
7d is included in a frequently deleted region of chromosome 9
(region B at 9q22.3). In breast carcinomas, a region of LOH (loss
of heterozygosity) at 11q23 was shown to harbor the cluster
miR-125b1/let-7a-2/miR-100, and the cluster miR-99a/let-7c/
miR-125b-2 resides at 21p11.1, a region of frequent HD (homozy-
gous deletions) in lung cancers. Furthermore, let-7a-1, let-7f-1,
let-7d and miR-202 are located close to class II homeotic genes
in the human HOX gene clusters [50].
The let-7 family plays crucial roles in cellular differentiation
and in development, and it displays speciﬁc temporal and spatial
expression patterns during development of several species
[48,51]. For example, in mammals, the level of let-7 increases dur-
ing embryogenesis and during brain development [52]. In concor-
dance with developmental roles for the let-7 family, members of
this family are also involved in cancer, and as discussed below,
many of them act as tumor suppressor miRNAs. Downregulation
of most let-7 family miRNAs was demonstrated in several types
of human cancer, including lung, head and neck squamous cellcarcinoma, breast, melanoma, ovarian and prostate cancers. Inter-
estingly, silencing all let-7 family members in ovarian cancer cell
lines increased cell survival, invasion and adhesion [53]. The
targets of let-7 are also conserved from worms to humans, and
they include known oncogenic transcripts, such as MYC and RAS
[54]. Interestingly, the viral homolog of KRAS contains a single
nucleotide polymorphism (SNP) in its potential let-7 binding site,
which increases the risk for lung, oral and colorectal cancers [55–
57]. Another cancer related target of the let-7 family is the
high-mobility group AT-hook 2 (HMGA2) oncoprotein, a chroma-
tin-associated non-histone protein that affects transcription by
modulating chromatin’s architecture [58].
Let-7c, a member of the let-7 family, functions as a tumor sup-
pressor in several types of cancer (Fig. 2). It regulates EMT [55] and
targets various oncogenes and cancer related genes [59], such as:
N-RAS [54], c-MYC [60], HMGA2 [58], MMP11, PBX2, PBX3, TRIB2,
ITGB3, TGFBR1 [61], BCL-XL and MAP4K3 (see Table 3). In support
of a role for let-7c as a tumor suppressor, its reduced expression
was demonstrated in tumors and cultured cells from prostate,
lung, colorectal and hepatocellular tumors [60,62–65]. Addition-
ally, downregulation of let-7c was associated with poor prognosis
in colorectal cancer, where let-7c expression was signiﬁcantly low-
er in patients presenting lymph node involvement or distant
metastases, compared to patients without any detectable metasta-
sis [65]. In non-small cell lung carcinoma (NSCLC), low expression
of let-7c was associated with poor patient survival, as well as with
tumor spread, venous invasion and advanced disease stages [64].
Interestingly, let-7c is encoded by chromosomal locus 21q21,
which shows loss of heterozygosity in lung cancer [66].
The maturation process of miRNAs of the let-7 family, including
that of let-7c, is regulated by the RNA-binding proteins called
Lin28 and Lin28B, which employ several different regulatory
mechanisms [67]. Lin28 is expressed in the cytoplasm and blocks
processing of let-7 by Dicer through direct binding to the terminal
loop of pre-let-7 and by recruiting the terminal uridyl transferase
(TUTase) Zcchc11/TUT4 to catalyze the oligouridine tail, thus
marking pre-let-7 for degradation [68,69]. Lin28B is found mainly
in the nucleolus, and upon binding to pri-let-7 it blocks the activity
of the microprocessor complex through TUTase-independent
mechanism (reviewed by [70]). Interestingly, miRNAs of the let-7
family have been suggested to reciprocally downregulate the
expression of Lin28 and Lin28B and thus increase the levels of
mature let-7 family miRNAs [71,72]. Let-7c’s expression levels
can also be regulated by the peroxisome proliferator-activated
receptor a (PPARa) in hepatocellular carcinoma cells [63].
Manipulation of let-7c expression in cancer cell lines further
established its role as a tumor suppressor. For example, overex-
pression of let-7c decreased, whereas depletion of let-7c increased
cell proliferation and clonogenicity of prostate cancer cells in vitro.
Let-7c also exerted an anti-proliferative effect in vivo, when tested
by intratumoral injection, which signiﬁcantly reduced tumor size
in xenografts of human prostate cancer cells [60]. According to
recent studies, let-7c can also function as a metastasis suppressor.
In highly metastatic colorectal adenocarcinoma cells, ectopic over-
expression of let-7c led to reduced migration and invasion in vitro,
and almost completely inhibited tumor growth and metastasis.
When tested in weakly metastatic cells, let-7c inhibition resulted
in increased cell motility and invasion. These effects of let-7c on
motility were likely mediated by targeting of KRAS, MMP11 and
PBX3 [65]. Additionally, ectopic let-7c expression in chemother-
apy-resistant lung adenocarcinoma cells reduced the number of
metastatic nodules in lung and liver, probably via inactivation of
the AKT pathway [55].
In addition to the AKT pathway, let-7c controls several other
cancer-related signaling pathways. Thus, let-7c plays an important
role in the regulation of androgen receptor (AR) signaling by
Fig. 2. Let-7c regulation and functions. The biogenesis of the let-7 family, including let-7c, is controlled by the RNA-binding proteins Lin28 and Lin28B. In particular, Lin28B
inhibits Drosha-mediated formation of pre-let-7, as well as Dicer-mediated formation of let-7 duplexes. In turn let-7 family members downregulate expression of Lin28 and
Lin28B, thereby establishing a negative feedback loop. Let-7c is downregulated in many types of tumors and its overexpression has a negative effect on cancer cells
proliferation, metastasis and epithelial to mesenchymal transition.
Table 3
miR-let7c target genes.
Tissue Target Function References
Lung cancer RAS
TRIB2
Inhibition of proliferation [54,136]
Bcl-xL Inhibition of chemo- or radioresistance and EMT [55]
ITGB3
MAP4K3
Inhibition of migration and invasion [64]
Acute myeloid leukemia PBX2 Inhibition of leukemogenesis [62]
Uterine leiomyoma HMGA2 Inhibition of proliferation [58]
Colorectal cancer MMP11
PBX3
Inhibition of metastatization [65]
Prostate cancer MYC Suppression of androgen receptor via regulation of MYC [60]
Kidney ﬁbrosis TGF-beta receptor 1 Inhibition of ﬁbrosis by suppression of a receptor for TGF-beta [61]
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eration. Accordingly, the expression of let-7c and AR are negatively
correlated in human prostate cancer, where AR, MYC and Lin28
expression levels are high while let-7c expression level is low
[60]. In acute leukaemia, let7-c targets PBX2, a homeodomain pro-
tein, which upon aberrant expression enhances HoxA9-dependent
leukemogenesis, and promotes granulocytic differentiation [62].
Let-7c may also suppress cell growth and control cancer pathogen-
esis by regulating the mitogen-activated protein kinase (MAPK)pathway. In lung adenocarcinoma, let-7c directly targets TRIB2,
which in turn activates the downstream components, C/EBP-a
and a phosphorylated p38-MAPK [73]. Another pathway by which
let-7c can regulate the MAPK pathway is through its role in con-
trolling NRAS expression [54]. One of the key metastasis-driving
processes is EMT [74], which is affected by several transcriptional
switches, including a let-7c regulated switch. Docetaxel-resistant
lung adenocarcinoma cells are characterized by ﬁbroblast-like
morphology and adhesion, which are typical of the mesenchymal
Table 4
miR-223 target genes.
Tissue Target Function References
Acute myeloid leukemia E2F1 Inhibition of proliferation [81]
Hepato-carcinoma STMN1
IGF-1R
ABCB1
Inhibition of proliferation and of multidrug resistance [86,85,137]
Lewis lung carcinoma CDK2 Inhibition of proliferation and invasion [88]
Colorectal cancer FOXO1 Inhibition of proliferation [89]
Glioblastoma PAX6 Proliferation invasion [138]
Breast cancer Caprin-1 Inhibition of proliferation and invasion [139]
Breast and colon cancer STMN1 Inhibition of chemoresistance [87]
Gastric cancer EPB41L3 Invasion and metastatization [140]
Esophageal carcinoma ARTN Inhibition of invasion and metastatization [141]
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these cells gained an epithelial phenotype, which might contribute
to the restoration of chemo- and radio-sensitivity. This effect of let-
7c is probably achieved through direct targeting of BCL-XL [55].
In summary, let-7c plays a crucial role in cancer pathogenesis
through targeting key cancer-related proteins and acting as a sup-
pressor of both tumor growth and tumor spread. Thus, let-7c might
be considered an attractive candidate for drug-induced manipula-
tion in cancer therapy.
1.3. miR-223 in cell differentiation and in tumor suppression
MiR-223 was initially identiﬁed as a miRNA nearly exclusively
expressed in bone marrow, such that its functional role in the
regulation of the cell fate determination of human hematopoietic
progenitors cells (HPCs) rapidly emerged [75,76]. Recently, Vian
and colleagues evidenced that in human CD34 + HPCs undergoing
unilineage differentiation/maturation, miR-223 is up-regulated
during granulopoiesis rather than during monocytopoiesis and is
maintained at low levels during erythropoiesis [77]. Interestingly,
miR-223 overexpression in human CD34 + HPCs favors granulopoi-
esis and impairs erythroid and monocytic/macrophagic differenti-
ation [77].
The ﬁne-tuning of miR-223 expression levels during hemato-
poietic differentiation of HPCs, as well as of myeloid cell lines, into
erythroid, granulocytic and monocytic/macrophagic lineages is the
result of the coordinated recruitment and function of lineage-spe-
ciﬁc transcription factors (TFs) on two different regulatory regions
of the miR-223 promoter [76,77]. For example, during granulocytic
differentiation of human myeloid progenitors, the induction of
miR-223 expression is transcriptionally regulated by competitive
binding of two transcription factors (TFs), Nuclear Factor I (NFI-
A) and CCAAT/enhanced-binding protein alpha (C/EBPa), to the
proximal miR-223 regulatory region. NFI-A maintains miR-223
transcription at low levels, while its replacement by C/EBPa results
in miR-223 induction and granulocytic differentiation [78]. NFI-A
was also identiﬁed as a target for miR-223 at transcriptional and
translational level, thus establishing a feedback regulatory cir-
cuitry in the control of granulopoiesis [76,79]. Interestingly, miR-
223 expression is downregulated in different subtypes of acute
myeloid leukemia (AML), which represents the clonal expansion
of hematopoietic precursors blocked at different stages of differen-
tiation [80]. In particular, primary blasts carrying the t(8;21)
generating AML1/ETO, the most common acute myeloid leuke-
mia-associated fusion protein, present very low expression levels
of miR-223. In these cells the AML1-ETO oncoprotein, which
recruits an epigenetic silencing complex consisting of HDACs,
DNMTs, and methyl-CpG-binding proteins on the AML1 binding
site of the miR-223 promoter, links the epigenetic silencing of a
miRNA locus to the differentiation block of this acute myeloid leu-
kemia subtype [80]. Of note, the enforced expression of miR-223 inprimary AML blasts and in AML cell lines affects cell cycle progres-
sion and enhances granulocyte differentiation [76,77,80,81].
The tumor suppressor function of miR-223 in acute myeloid
leukemia is further supported by a recent study showing that
the induction of miR-223 inhibits the translation of the cell-cycle
regulator E2F1 and signiﬁcantly down-regulates the proliferation
rate of myeloid progenitors cells [81]. Of note, E2F1 transcription-
ally represses miR-223 gene in AML cells, suggesting that miR-
223 functions as a key regulator of myeloid cell proliferation is
strictly linked with E2F1 activity in a mutual negative feedback
loop.
Exosomes or micro-vesicles are emerging as important media-
tors of intercellular cross-talk for the regulation of a variety of
biological functions, such as cellular communication, proliferation
and differentiation [82]. Micro-vesicle transfer represents a novel
mechanism by which inﬁltrating mononuclear phagocytes may
contribute to cellular activation, survival, and immune function.
MiR-223 was evidenced to be the most highly expressed miRNA
in the macrophage-derived micro-vesicles that are able to induce
cellular differentiation when added to naive monocytes, support-
ing a functional ampliﬁcation loop to enhance immune function
(Fig. 3A) [83].
In addition to the exosome-mediated transfer of nucleic acids,
tissue macrophages were also shown to be able to transfer miR-
223 to hepatocarcinoma cells (HCCs) in a manner that required
intercellular contact and gap junction communication (Fig. 3B)
[84]. Functionally, the transfer of miR-223 from macrophages to
HuH7 cells resulted in the inhibition of proliferation of these HCCs
cancer cells, thus highlighting intercellular transfer of miRNA from
immune cells as a new, possible mechanism of defense against
neoplastic cell transformation or tumor growth [84]. The transfer
of miR-223 inﬂuences protein expression in HuH7 cells. Speciﬁ-
cally, miR-223 decreases the expression of Stathmin-1 (STMN1)
and insulin-like growth factor-1 receptor (IGF-1R), which both
inﬂuence cellular proliferation and can support the growth of tu-
mors [85,86]. STMN1 is a key microtubule-regulatory protein that
controls microtubule dynamics, cell proliferation and, in particular,
the S-phase of the cell cycle. High-levels of STMN1 have been asso-
ciated with increased histologic grading, shorter patient survival
times, and increased drug resistance in different tumors. STMN1
is a protein that is usually present at low levels in healthy hepato-
cytes but is expressed at high levels in hepatocarcinomas [86]. In
HCC cell lines, a strong inverse relationship between STMN1’s
mRNA and miR-223 expression was observed and a substantial
reduction in STMN1 protein was demonstrated upon restoration
of miR-223 expression, resulting in a consistent inhibitory effect
on cell viability [86].
Consistent with these lines of evidence, it was recently reported
that modulation of miR-223/STMN-1 pathway represents another
way by which mutant p53 increases cellular resistance to chemo-
therapeutic drugs [87]. The induction of mutant p53R175H in breast
Fig. 3. Macrophage-mediated miR-223 transfer. (A) miR-223 is released by macrophages into micro-vesicles and it induces cellular differentiation of naive monocytes to
increase in immune functions. (B) Macrophages mediate miR-223 transfer to cancer cells by mean of cell contact and gap junction communication. The transferred miR-223 is
functionally active, and through decreased expression of Stathmin-1 (STMN1) and insulin-like growth factor-1 receptor (IGF-1R), it induces growth arrest of cancer cells.
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p53R175H, together with the transcriptional repressor ZEB-1, binds
to the miR-223 promoter and decreases miR-223 expression,
resulting in an up-regulation of STMN-1 and in an increased cellu-
lar resistance to chemotherapeutic agents. On the contrary, ectopic
expression of miR-223 can lower the levels of STMN-1 and sensi-
tize breast and colon cancer cell lines expressing mutant p53 to
treatment with DNA-damaging drugs [87].
By targeting IGF-1R and the cyclin-dependent kinase 2 (CDK2),
miR-223 functions as a potent tumor suppressor also in the Lewis
lung carcinoma (LLC) cell line [88]. Ectopic expression of miR-223
suppresses proliferation, invasion and tumorigenicity of LLC cells,
induces G2/M phase arrest and inhibits tumor growth in vivo, pro-
viding the basis for novel therapies targeting IGF-1R in the treat-
ment of NSCLC [88].
The inhibition of cancer cell proliferation by miR-223 was
recently reported also in colorectal cancer [89]. The colorectal
cancer HCT116 cells express very low levels of endogenous
miR-223 and overexpression of miR-223 in these cells reduces
mRNA and protein expression levels of FOXO1, whose abnormal
expression or activation can result in aberrant apoptotic path-
ways, proliferation, and cell cycle regulation. Interestingly, miR-
223 overexpression mainly increases the un-phosphorylated
FOXO1 protein, its nuclear localization, as well as cyclin D1/
p21/p27 at either mRNA or protein accumulation and inhibition
of tumor cell proliferation [89].
Although several experimental lines of evidence support the
involvement of miR-223 in cell differentiation and tumor suppres-
sion, miR-223 was also reported to be up-regulated in some tu-
mors and to contribute to leukemogenesis in speciﬁc disease
subtypes (T-ALL), indicating that the biological effect of miR-223
strongly depends on the cellular context where this miRNA specif-
ically performs its function [90,91] (see Table 4).1.4. miR-145 in tumor suppression
miR-145 is located at chromosome 5q33.1 and is usually tran-
scribed in a bicistronic primary transcript with miR-143 [92]. Of
note, miR-145 represents one of the miRNAs that are highly ex-
pressed in normal tissues but they are down-regulated in several
human cancers, including colorectal and breast cancer [41,93].
Although the downregulation of miR-145 expression in human
cancer may result from genetic aberrations, as occurs in hemato-
logical malignancies associated with the 5q- syndrome phenotype
[94], a major mechanism for the modulation of miR-145 expres-
sion is represented by transcriptional and post-transcriptional con-
trol. Interestingly, transcriptional contribution to the regulation of
miR-145 expression was reported in breast and in colon cancer,
cell lines where p53, by interacting with a consensus sequence in
the miR-145 promoter, transcriptionally induces miR-145 expres-
sion, promoting the post-transcriptional downregulation of MYC
and consequently the inhibition of tumor cell growth [95]. In line
with these results, in prostate cancer tissues and in cell lines,
miR-145 was found to be silenced through the methylation of its
promoter, and miR-145 silencing was signiﬁcantly correlated to
the status of the p53 gene [96]. A recent study also reported that
the CCAAT/enhancer binding protein beta (C/EBPb) is able to coun-
teract the p53-mediated induction of miR-145. In fact, C/EBPb in-
duces the transcriptional downregulation of miR-145 expression
by interacting with a CCAAT binding site located within the miR-
145 promoter; this downregulation seems to be independent from
p53 and it involves the AKT pathway [95,97].
Concerning miR-143/miR-145 processing, it was recently
reported that p53 itself might be involved in the post-transcrip-
tional maturation of several miRNAs with growth-suppressive
functions, in response to DNA damage, including miR-143/miR-
145. In particular, the p53 protein, through an association with
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with the Drosha processing complex, thus supporting the process-
ing of primary miRNAs to precursor miRNAs. On the contrary, p53
mutated proteins interfere with the functional assembly between
the Drosha complex and p68, inducing an attenuation of miRNA
processing activity [98]. Moreover, it was also recently reported
that the DEAD-box RNA helicase 6 (DDX6), that is highly expressed
in most malignant cells, post-transcriptionally down-regulates
both miR-143 and miR-145 expression. In human gastric cancer
cells, DDX6 protein, that is abundantly expressed and accumulated
in processing bodies (P-bodies) containing many proteins involved
in mRNA turnover, negatively regulates the RNA stability of the
bicistronic primary transcript resulting in the downregulation of
both miR-143 and miR-145 [99]. Several reports, supporting miR-
145’s action as a tumor suppressor in different tumor types, have
revealed that the downregulation of miR-145 expression is associ-
ated with neoplastic cell growth and proliferation, as well as with
cancer cell migration, invasion and metastasis (Table 5) [100–104],
In colon cancer, the tumor suppressor function of miR-145 was
initially related to the downregulation of the insulin receptor sub-
strate-1 (IRS-1). Of note, in human colon cancer cells miR-145, by
targeting the 30 UTR of IRS-1, dramatically down-regulates the IRS-
1 protein, thereby inducing cell growth arrest [105]. In colon
cancer cell lines, YES and STAT1 factors were also evidenced as
additional miR-145 targets [106]. Interestingly, in colon cancer tis-
sues, low miR-145 expression level is inversely correlated to
p70S6K1 protein levels. On the contrary, the forced expression of
miR-145, by targeting p70S6K1, resulted in the downregulation
of two downstream molecules of p70S6K1 pathway, the VEGFA
and HIF-1a proteins, thus inhibiting tumor growth and angiogene-
sis [107].
The tumor suppressive function of miR-145 on cancer cell pro-
liferation was also recently reported in lung cancer. By targeting
the EGFR and nucleoside diphosphate linked moiety X-type motif
1 (NUDT1), miR-145 inhibits lung adenocarcinoma cell prolifera-
tion and lung tumorigenesis [108]. Of note, the prognostic value
of miR-145 was originally evidenced in lung cancer, where the
low expression miR-145 is signiﬁcantly correlated with a worse
prognosis and survival of adenocarcinoma patients [109].
In breast cancer tissues, miR-145 expression is inversely corre-
lated with the stage of malignancy. In particular, miR-145, through
the post-transcriptional regulation of N-RAS and VEGFA expres-
sion, exhibits inhibitory roles in tumor angiogenesis, invasion
and tumor growth [110]. Accordingly, in the human breast cancer
cell line MCF-7, miR-145 induction was shown to promote the
inhibition of cell growth and the induction of apoptosis byTable 5
miR-145 target genes.
Tissue Target Funct
Colon cancer IRS-1
YES and STAT1
c-Myc
Grow
p70S6K1 Grow
JNK and MAPK pathways Colon
CD44, KLF5, KRAS, BRAF Trans
Lung cancer EGFR, NUDT1 Prolif
Breast cancer MUC1
JAM-A and fascin
Migra
N-RAS and VEGFA
RTKN
Angio
p53 pathway and ER-alpha Prolif
Zeb2 and Klf4 Cance
Mesothelioma OCT4 Grow
Pancreatic cancer KRAS and RREB1 KRAS
Prostate cancer BNIP3
FSCN1
ERG
Proliftargeting the Rho-effector rhotekin (RTKN) [111]. A death-promot-
ing loop between miR-145 and TP53 was also identiﬁed in MCF7
breast cancer cells expressing wild-type TP53. miR-145 indeed
activates the p53 pathway, resulting in the promotion of apoptosis,
and sustaining in turn a further induction of miR-145 expression.
In the same context, miR-145 may also down-regulate estrogen
receptor-alpha (ER-a) protein expression, whereby a miR-145
re-expression therapy was proposed, at least for the subgroup of
patients with ER-a-positive and/or TP53 wild-type tumors [112].
Interestingly, the re-expression of miR-143/miR-145 was also
shown to suppress cellular growth and to support the apoptosis
of epithelial cancer cells by enhancing p53 activity via MDM2 turn-
over [113].
The involvement of miR-145 in an integrated transcriptional
regulatory circuit together with TFs and chromatin-modifying
activities that support the growth and function of breast cancer
stem-like cells (CSCs) recently emerged [114]. Accordingly, previ-
ous results evidenced that expression of miR-145 is low in self-
renewing human embryonic stem cells (hESCs) but highly up-reg-
ulated during differentiation. Increased miR-145 expression inhib-
its hESC self-renewal, represses expression of pluripotency genes,
such as OCT4, SOX2, and KLF4, and induces lineage-restricted dif-
ferentiation [115].
In malignant pleural mesothelioma (MPM) cells, miR-145 has
the potential to modulate many pro-tumorigenic features, includ-
ing growth, clonogenicity and tumor engraftment in vivo. Interest-
ingly, in MPM cells miR-145 targets directly OCT4 and, indirectly,
the EMT-promoting target ZEB1. Of note, the levels of miR-145
and OCT4 are inversely correlated in vivo. Promoter hyper-methyl-
ation may contribute to the low levels of miR-145 in both MPM
cells and in malignant MPM tissues. Importantly, miR-145 down-
regulation has been proposed to differentiate benign from malig-
nant mesothelial tissues [116].
In pancreatic cancer cells, the activation of the KRAS signaling
pathway consistently leads to the repression of the miR-143/
miR-145 cluster and this is necessary to maintain the tumorigenic
potential of these cancer cells. The downregulation of miR-143/
miR-145 expression requires the RAS-responsive element-binding
protein (RREB1), which represses the miR-143/miR-145 promoter.
Both KRAS and RREB1 transcripts are direct targets of these miR-
NAs (see Table 5), demonstrating the existence of a feed-forward
pathway that potentiates KRAS-mediated tumorigenesis [117].
More recently, the RREB1 protein was found to be overexpres-
sed in colorectal adenocarcinoma tumors and cell lines, where
the expression of the miR-143/miR-145 primary transcript is in-
versely related to that of RREB1. RREB1 negatively regulatesion References
th and proliferation [105,106]
th and angiogenesis [95]
y and tumor formation [107]
formation properties [118]
eration and tumorigenesis [108]
tion and invasion [100,101]
genesis, invasion and growth [110]
eration and apoptosis [111]
r stem-like cells function [112]
th and clonogenicity [116]
-mediated tumorigenesis [117]
eration, migration, invasion, EMT and metastasis [120,104,122]
Table 6
miR-204 target genes.
Tissue Target Function References
Eye Meis2
Sox11
Lens and retina development [126,125]
Gastric cancer BCL-2
SIRT-1
Apoptosis MET [127,130]
Head and neck cancer Multiple targets Inhibition of metastatization [131]
Endometrial carcinoma TrKB Inhibition of clonogenic growth, migration and invasion [132]
Glioma Sox4
EphB2
Inhibition of stem-cell likephenotype and migration [133]
Renal cell carcinoma LC3B Inhibition of macroautophagy [134]
Pancreatic cancer Mcl-1 Apoptosis [142]
Breast cancer IL-11 Inhibition of metastatization [143]
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manner, thus establishing a complex network of regulation
through which the miR-143/miR-145 cluster is able to modulate
KRAS signaling [118]. In line with this, additional direct and indi-
rect miR-143/miR-145 target genes have been reported, and they
belong to the growth factor receptor-mitogen-activated protein
kinase network, as well as to the p53 signaling pathway, further
supporting a contribution of miR-143/miR-145 to the cell signaling
pathways involved in colorectal tumorigenesis [119].
In prostate cancermiR-145 is consistently downregulated. A sig-
niﬁcant inverse correlation between the expression of miR-145 and
that of the BNIP3 protein was observed in prostate cancer and in in
benign prostate tissues. Accordingly, the overexpression ofmiR-145
in prostate cancer PC-3 and DU145 cells signiﬁcantly down-regu-
lated BNIP3, reduced cell growth, and increased cell death. As afore-
mentioned for breast and colon cancer, the overexpression of
wild-type p53 resulted in the up-regulation of miR-145 expression
also in PC-3 cells, with consequent pro-apoptotic effects [120].
Wild-type p53 induces up-regulation of miR-145 expression and
the inhibitory effects of wild-type p53 on migration, invasion, EMT
and stemness of PC-3 cells were reversed by anti-miR-145. These re-
sults suggest that loss of wild-type p53may promote bonemetasta-
sis of prostate cancer, at least partially through miR-145
downregulation, and resulting in increased EMT and stemness of
cancer cells [121]. Moreover, the ectopic expression of miR-145 in
LNCaP and DU145 cell lines led to a reduction in the expression of
the ERG protein, suggesting that downregulation ofmiR-145 associ-
ated with prostate cancer may contribute to the increased expres-
sion of several ERG isoforms that are frequently observed in this
tumor type [122] .
In conclusion, several lines of evidence indicate that miR-145
may be largely considered a miRNA with tumor suppressor
activity, which is involved in the regulation of tumor growth, cell
invasion and metastasis by targeting multiple cancer related genes,
thus offering miR-145 as a novel therapeutic target for cancer
therapy.
1.5. MiR-204: a key player in development and in tumor suppression
MiR-204 is encoded by the cancer associated genomic region
(CAGR), the 9q21.1-q22.3 locus that exhibits high frequency of loss
of heterozygosity in diverse human cancers [123]. MiR-204 is an
intragenic miRNA, which is located within the transient receptor
potential melastatin-3 (TRPM3) gene belonging to the family of
transient receptor potential (TRP) channels [124].
MiR-204 activity is highly involved in vertebrate lens develop-
ment and its loss is evidenced in different human cancers
(Fig. 4). Banﬁ’s group has shown that miR-204 is highly expressed
in retinal pigment epithelium, lens, ciliary body and neural retina
[125]. Its activity is required for the proper development of lens
and optic cups [125]. The TF Meis2 is a main target of thedevelopmental activity of miR-204. Aberrant expression of Meis2
released by miR-204 downregulation leads to lens abnormalities,
microphthalamia, and eye coloboma [125]. Interestingly, miR-
204 and its host gene TRMP3 are transcriptionally co-regulated
by the developmental TF PAX6 [126]. The analysis of genes aber-
rantly expressed in PAX6 mutants during eye development
revealed that miR-204 target genes are highly represented. This
led to identiﬁcation of novel developmental target genes of miR-
204, such as Sox11, a member of the SoxC family of neuronal
TFs, which plays a critical role in normal eye development. Intrigu-
ingly, PAX6 exerts its transcriptional program either by modulating
directly the expression of its targets genes, or by indirectly modu-
lating the expression of miR-204 that controls that of mRNA tar-
gets. This gives rise to a complex regulatory network that tunes
and integrates coding and non-coding gene expression to pursue
proper development.
Growing evidence indicates that miR-204 downregulation is a
common alteration in different types of human tumors. MiRNA
expression proﬁling of three different subsets of gastric cancer
patients revealed that miR-204 expression was down-regulated in
tumoral specimens when compared to matched peri-tumoral tis-
sues [127]. TRPM3 gene loss was evidenced in a large fraction of
the analysed gastric patients. Hence, this might be one of the
molecular mechanisms underlying miR-204 downregulation in hu-
man cancers [127–129]. Notably, gastric cancer patients can be
grouped according to the extent of miR-204 downregulation. Those
characterized by a severe reduction (more than 0.5-fold) had the
worst survival when compared to those with mild downregulation
of miR-204 (less than 0.5-fold) [127]. The pivotal anti-apoptotic
protein, BCL-2, was shown to be a target of miR-204. Reduced
expression of miR-204 paired with increased staining of BCL-2 in
gastric cancer patients [127]. BCL-2 ectopic expression counter-
acted the pro-apoptotic role of miR-204 in response to 5-Fluoroura-
cil [127]. Downregulation of miR-204 in gastric cancers was also
associated with increased expression of the class III histone deace-
tylase SIRT1. The targeting of SIRT1 by miR-204 ectopic expression
favored mesenchymal to epithelial transition (MET) phenotypes
and suppressed anoikis resistance of gastric cancer cells [130].
Notably, network modelling performed in head and neck tumors
by the combination of gene expression data with inheritable cancer
traits and risk factor loci uncovered 18 targets of miR-204 that are
mainly involved in the development of metastasis [131]. Interest-
ingly, ectopic expression of miR-204 not only reduced the levels
of its target genes but also resulted in the inhibition of metastatic
phenotype of head and neck cancer cell lines [131]. Altogether
the localization of miR-204 linked the 9q21.1-q22.3 CAGR locus, a
very well known risk factor for head and neck tumors, and the iden-
tiﬁed target genes, thus accounting for a bona-ﬁde tumor suppres-
sor micro-RNA. Downregulation of miR-204-5p was also evidenced
in endometrial carcinomas (EC), when compared to normal endo-
metrium [132]. This might result from the aberrant expression of
Fig. 4. miR-204 functions. miR- 204 plays important roles in both eye development (A) and in tumor suppression (B). During eye development, high levels of miR-204 induce
a reduction in Meis2 and Sox11 protein expression, thereby modulating the expression of other target proteins that contribute to normal development of the lens and retina.
In particular, miR-204 expression is positively regulated by Pax6, a regulator of multiple processes during eye development, that in turn is activated by Meis2. Hence, miR-
204 and Pax6 co-regulate each other via a negative feedback loop. miR-204 is downregulated in different types of cancer. Its tumor suppressor activity is mediated by the
modulation of the expression of different oncoproteins depending on the cellular context.
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of miR-204 [132]. Ectopic expression of TrkB led to the accumula-
tion of phospho-STAT3 that was recruited to a speciﬁc binding site
of the miR-204’s host gene, TRMP3, and might account for miR-204
downregulation in EC [132]. Loss of miR-204 expression through
promoter methylation was evidenced in both glioma and neural
stem cells [133]. This led to enhanced migration of glioma cells
and to the acquisition of a stem cell-like phenotype. Indeed, atten-
uation of promoter methylation increased miR-204 expression in
glioma cells and ectopic expression of miR-204 suppressed the
tumorigenic potential of glioma cells. Mechanistic investigation re-
vealed that miR-204 targets the expression of SOX4, a stemness TF,
and EphB2, a receptor that promotes migration [133].
MiR-204 is a transcriptional target of the von Hippel-Lindau
tumor suppressor gene (VHL) that is lost in the largest fraction of
clear cell renal cell carcinomas (ccRCC) [134]. VHL-induced expres-
sion of miR-204 resulted in increased expression of short tran-
scripts of TRMP3, thus indicating that miR-204 is not, at least in
ccRCC, transcriptionally co-regulated with the large transcript
encoding the full-length TRMP3 protein [134]. MiR-204 expression
is clearly reduced in ccRCC with known VHL status when compared
to matched normal kidney samples and its reconstitution led to
growth inhibition in vitro and in vivo [134]. The transcriptional tu-
mor suppressor axis VHL/miR-204 inhibited macroautophagy. This
occurs through the ability of miR-204 to directly target LC3B and
VHL-induced expression of the parolog, LC3C, which caused
growth suppression.It appears increasingly clear, that both in development and in
cancer the downregulation of miR-204 disables coordinated tran-
scriptional networks and instigates unscheduled signaling path-
ways (see Table 6). These might contribute to developmental
diseases or to aberrant proliferation, metastasis and poor response
to conventional anticancer treatments. The identiﬁcation of addi-
tional miR-204 targets and the dissection of the epigenetic events
regulating its expression in normal and in malignant tissues might
provide intriguing insights, which would make miR-204 an appeal-
ing and hopefully druggable target.
1.6. Perspectives and open questions
Collectively, the reviewed groups of tumor suppressor miRNAs
are emerging as major players of the cellular response to different
types of oncogenic insults. Together with coding RNAs, epigenetic
modiﬁcations and other mechanisms, this response can lead to clo-
nal expansion, migration and invasion, as well as chemoresistance
of a given tumor. Along with ever improving understanding of the
concerted alterations in miRNAs, many cardinal questions remain
open. For example, it is logical that tumor suppressor miRNAs
maintain complex crosstalks with protein coding tumor suppressor
RNAs in order to fortify barriers to oncogenicity, but the details of
this interplay are currently unknown. Also unknown are the
molecular determinants underlying activation of intragenic and
intergenic tumor suppressor miRNAs upon oncogenic insults. The
multiplicity of RNA targets of each tumor suppressor miRNA poses
G. Blandino et al. / FEBS Letters 588 (2014) 2639–2652 2649a pivotal challenge. Moreover, it is conceivable that the tumor cell
context inﬂuences target speciﬁcity, and consequently determines
biological effects. These and additional issues will require deeper,
perhaps more integrated understanding of tumor suppressor
miRNAs.
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